Jazz Pharmaceuticals (JAZZ) Operating Expenses (2010 - 2026)

Jazz Pharmaceuticals' Operating Expenses history runs 17 years deep, the most recent figure standing at $732.3 million for Q1 2026.

• In Q1 2026, Operating Expenses fell 23.21% year-over-year to $732.3 million; the TTM figure through Mar 2026 stood at $4.5 billion (up 28.99% YoY), while the FY2025 annual figure was $4.7 billion, up 40.14% from the prior year.
• Operating Expenses was $732.3 million for Q1 2026 at Jazz Pharmaceuticals, down from $943.4 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $1.7 billion in Q2 2025 to a low of $726.2 million in Q1 2022.
• Historically, Operating Expenses has averaged $927.2 million across 5 years, with a median of $847.3 million in 2022.
• The sharpest annual moves came in 2023 and 2025: Operating Expenses slipped 28.01% in 2023, then soared 110.11% in 2025.
• A 5-year view of Operating Expenses shows it stood at $1.2 billion in 2022, then retreated by 28.01% to $889.4 million in 2023, then grew by 0.9% to $897.4 million in 2024, then climbed by 5.12% to $943.4 million in 2025, then slipped by 22.38% to $732.3 million in 2026.
• The last three Operating Expenses figures came in at $732.3 million (Q1 2026), $943.4 million (Q4 2025), and $1.1 billion (Q3 2025), per Business Quant data.